CorMedix Historical Income Statement
| CRMD Stock | USD 8.57 0.30 3.38% |
Historical analysis of CorMedix income statement accounts such as Selling General Administrative of 37.6 M, Research Development of 10.2 M or Depreciation And Amortization of 79.6 K can show how well CorMedix performed in making a profits. Evaluating CorMedix income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CorMedix's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining CorMedix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CorMedix is a good buy for the upcoming year.
CorMedix |
About CorMedix Income Statement Analysis
CorMedix Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CorMedix shareholders. The income statement also shows CorMedix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
CorMedix Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CorMedix. It is also known as CorMedix overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from CorMedix operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CorMedix is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Most accounts from CorMedix's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CorMedix current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.At present, CorMedix's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 51.4 M, whereas Research Development is forecasted to decline to about 10.2 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 177.0K | 209.0K | 70.8K | 79.6K | Research Development | 13.1M | 10.7M | 13.2M | 10.2M |
CorMedix income statement Correlations
Click cells to compare fundamentals
CorMedix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CorMedix income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 787.5K | 33.2K | 15.9K | 26.5K | 34.3K | 32.6K | |
| Selling General Administrative | 9.9M | 13.9M | 16.3M | 20.0M | 35.8M | 37.6M | |
| Research Development | 11.1M | 13.4M | 13.1M | 10.7M | 13.2M | 10.2M | |
| Depreciation And Amortization | 171.9K | 143.5K | 177.0K | 209.0K | 70.8K | 79.6K | |
| Other Operating Expenses | 21.3M | 27.5M | 29.5M | 30.7M | 49.0M | 51.4M | |
| Operating Income | (21.0M) | (27.2M) | (29.4M) | (30.6M) | (49.0M) | (46.5M) | |
| Ebit | (20.9M) | (27.2M) | (29.6M) | (30.3M) | (49.0M) | (46.5M) | |
| Ebitda | (20.7M) | (27.0M) | (29.4M) | (30.1M) | (48.9M) | (46.4M) | |
| Total Operating Expenses | 20.9M | 27.3M | 29.5M | 30.7M | 49.0M | 51.4M | |
| Income Before Tax | (21.5M) | (27.2M) | (29.5M) | (30.3M) | (46.3M) | (44.0M) | |
| Total Other Income Expense Net | (486.0K) | 23.7K | (22.8K) | 336.6K | 2.6M | 2.7M | |
| Net Income | (16.4M) | (22.0M) | (28.2M) | (29.7M) | (46.3M) | (44.0M) | |
| Income Tax Expense | (5.1M) | (5.2M) | (1.3M) | (585.6K) | (2.0) | (2.1) | |
| Total Revenue | 329.3K | 429.8K | 283.3K | 239.2K | 190.9K | 65.4K | |
| Gross Profit | (90.0K) | 34.4K | 42.0K | 61.7K | (205.6K) | (195.3K) | |
| Net Income From Continuing Ops | (16.4M) | (22.0M) | (28.2M) | (29.7M) | (46.3M) | (44.0M) | |
| Cost Of Revenue | 373.2K | 204.8K | 148.9K | 3.7K | 205.6K | 235.3K | |
| Non Operating Income Net Other | 34.6K | 301.8K | 23.7K | (22.8K) | (26.3K) | (27.6K) | |
| Net Income Applicable To Common Shares | (43.5M) | (22.0M) | (28.2M) | (29.7M) | (26.7M) | (28.1M) | |
| Interest Income | 322.7K | 116.1K | 14.4K | 326.0K | 2.7M | 2.8M | |
| Net Interest Income | (464.8K) | 82.8K | (1.5K) | 299.5K | 2.6M | 2.8M | |
| Reconciled Depreciation | 73.3K | 128.0K | 61.9K | 84.6K | 70.8K | 83.2K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.